MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.

MEI issued the following statement:

With the special meeting just days away, now is the time for MEI shareholders to vote FOR our pending Infinity transaction.

As a reminder, Independent leading proxy advisory firms, ISS and Glass Lewis, both recommend that MEI shareholders vote FOR the Infinity transaction. In making their recommendations, both ISS and Glass Lewis recognize the strategic benefits of our combination with Infinity.

MEI shareholders have an opportunity to participate in the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs.

A vote FOR the transaction is a vote FOR:

• Creating a diversified pipeline of three clinical-stage development programs that have the potential, in combination with current therapies, to overcome known resistance mechanisms.
• Providing potential opportunities for near-term value creation from upcoming data that is expected to be released over the next approximate 6-24 months.
• Benefiting from the clinical development and regulatory expertise of the MEI and Infinity teams in developing pharmaceutical products to treat cancer.

Don’t miss out. We encourage you to vote today FOR the transaction and enable our combined company to be well positioned to create value for shareholders and deliver improved therapeutic options for patients.

YOUR VOTE IS IMPORTANT!
VOTE “FOR” THE TRANSACTION WITH INFINITY PHARMACEUTICALS TODAY

MEI Pharma has scheduled the special meeting to approve the proposed transaction with Infinity on July 14, 2023. All shareholders of record as of the close of business on May 24, 2023 are entitled to vote at the special meeting.

Shareholders who have questions or need assistance voting your shares, please contact Alliance Advisors, MEI’s proxy solicitor:

Alliance Advisors, LLC
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003
[phone]
Email: [e-mail]

Stifel is serving as financial advisor to MEI Pharma and Morgan Lewis is serving as legal counsel.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma’s portfolio of drug candidates includes clinical stage candidates with differentiated mechanisms of action intended to address unmet medical needs and deliver improved benefit to patients, either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com. Follow us on Twitter @MEI_Pharma and on LinkedIn.